Monoclonal antibody · Antagonist of B-cell activating factor receptor (TNFRSF13C) · developed by Novartis Pharmaceuticals
Ianalumab is a fully human monoclonal antibody that binds the B-cell activating factor receptor (BAFF-R, TNFRSF13C), inhibiting BAFF binding and BAFF-R-mediated signaling that supports B-cell proliferation and survival. It is being studied in primary immune thrombocytopenia (ITP).
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05653349 | Phase 3 | Primary Immune Thrombocytopenia (ITP) | Active not recruiting | NVS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Primary Immune Thrombocytopenia (ITP)
Updated Nov 15, 2026. Something wrong or missing? Report it on the NVS page.
See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVS catalysts and pipeline →